SCHEMBL22855701

SCHEMBL22855701

COc1ccc(C(OC[C@@H](O)COC(=O)NCCCNC(=O)CO[C@@H]2O[C@H](COC(C)=O)[C@H](OC(C)=O)[C@H](OC(C)=O)[C@H]2NC(C)=O)(c2ccccc2)c2ccc(OC)cc2)cc1

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ LMNA P02545 3/20 0.45
▸ KMT2A Q03164 2/20 0.45
▸ ALDH1A1 P00352 4/20 0.43
▸ POLB P06746 2/20 0.43
▸ MAPT P10636 4/20 0.40
▸ CYP3A4 P08684 4/20 0.40
▸ CYP2C19 P33261 2/20 0.40
▸ CYP2C9 P11712 2/20 0.40
▸ KDM4E B2RXH2 1/20 0.39
▸ MMP12 P39900 3/20 0.36
▸ MMP9 P14780 2/20 0.35
▸ TGM2 P21980 1/20 0.34
▸ TSHR P16473 1/20 0.34
▸ CYP2D6 P10635 2/20 0.34
▸ CA12 O43570 3/20 0.33
▸ CA9 Q16790 3/20 0.33
▸ CA1 P00915 2/20 0.33
▸ CA2 P00918 2/20 0.33
▸ MEN1 O00255 1/20 0.33
▸ TP53 P04637 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22830211 0.89 LMNA (0.36) LMNAKMT2AALDH1A1POLBMAPT
SCHEMBL22855704 0.89 LMNA (0.37) LMNAKMT2AALDH1A1POLBMAPT
SCHEMBL22855721 0.87 LMNA (0.41) LMNAKMT2AALDH1A1POLBMAPT
SCHEMBL29934233 0.87 LMNA (0.40) LMNAKMT2AALDH1A1POLBMAPT
SCHEMBL22855324 0.86 LMNA (0.40) LMNAKMT2AALDH1A1POLBMAPT
SCHEMBL21345019 0.85 LMNA (0.34) LMNAKMT2AALDH1A1MAPTCYP3A4
SCHEMBL29929081 0.83 LMNA (0.46) LMNAKMT2AALDH1A1POLBMAPT
SCHEMBL22855650 0.83 LMNA (0.36) LMNAKMT2AALDH1A1POLBMAPT
SCHEMBL22855464 0.82 POLB (0.46) LMNAKMT2AALDH1A1POLBMAPT
SCHEMBL29742114 0.81 LMNA (0.42) LMNAKMT2AALDH1A1POLBMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3763815-A1 THERAPEUTIC AGENT FOR GLYCOGEN STORAGE DISEASE TYPE IA Daiichi Sankyo Company, Limited (JP) 2021-01-13 — — EP disclosed
US-20200407394-A1 THERAPEUTIC AGENT FOR GLYCOGEN STORAGE DISEASE TYPE IA DAIICHI SANKYO COMPANY, LIMITED (JP) 2020-12-31 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200407394-A1 THERAPEUTIC AGENT FOR GLYCOGEN STORAGE DISEASE TYPE IA G6PC1, GAA, GBA3 LMNA 241/4885KMT2A 3060/4885ALDH1A1 1979/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback